MTHFR and myeloid sarcoma: In previous studies, higher rates of homozygous methylenetetrahydrofolate reductase (MTHFR) mutations have been found among patients with autoimmune features and MS-like or vasculitic CNS disease, and a link has been identified between anti-thyroid antibodies with nonspecific WMH and CNS involvement in the setting of APS (Mavragani et al., 2007; Mavragani et al., 2009).